| Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. | |
| | |
MedLine Citation:
|
PMID: 19934818 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To compare the effectiveness of three consecutive intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in patients with treatment-naïve neovascular age-related macular degeneration. METHODS: This is a retrospective comparative study of qualifying consecutively treated patients (n = 176) with new-onset subfoveal choroidal neovascularization presenting at 6 retina referral centers. Patients were treated with 3 consecutive monthly injections of ranibizumab (0.5 mg) or 3 injections of bevacizumab every 6 weeks (1.25 mg) as determined by physician and patient preference. Ophthalmologic evaluations included monthly visual acuity measurements, ocular examinations, and optical coherence tomography imaging at each visit. RESULTS: A 29.2% reduction in the mean central foveal thickness measurement through optical coherence tomography was found in the ranibizumab-treated patients versus a 20.9% reduction in the bevacizumab-treated patients (P <or= 0.02). Fifty-three percent of ranibizumab-treated patients had returned to a central foveal thickness of <200 microm by the completion of 3 injections compared with 35% of patients treated with bevacizumab (P <or= 0.07). No ocular or systemic adverse events were reported in either group. CONCLUSION: Short-term effectiveness of ranibizumab treatment, as measured by incremental improvement in optical coherence tomography parameters, was significantly greater than bevacizumab treatment, suggesting that there is a difference in the biologic activities of ranibizumab and bevacizumab. |
| | |
Authors:
|
Tom S Chang; Gregg Kokame; Raynor Casey; Jonathan Prenner; Leonard Feiner; Nick Anderson |
Related Documents
:
|
7038578 - A prospective study of the use of hyperopic epikeratophakia grafts for the correction o... 19396788 - Linear regression analysis of the cumulative defect curve by sectors and other criteria... 11927428 - Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison... 17720068 - Incidence of visually significant pseudophakic macular edema after uneventful phacoemul... 10231628 - Infrarenal aortic surgery with a 3-day hospital stay: a report on success with a clinic... 23075858 - Comparison of direct pars repair techniques of spondylolysis in pediatric and adolescen... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study |
Journal Detail:
|
Title: Retina (Philadelphia, Pa.) Volume: 29 ISSN: 1539-2864 ISO Abbreviation: Retina (Philadelphia, Pa.) Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: 2010-01-13 Revised Date: 2013-05-27 |
Medline Journal Info:
|
Nlm Unique ID: 8309919 Medline TA: Retina Country: United States |
Other Details:
|
Languages: eng Pagination: 1235-41 Citation Subset: IM |
Affiliation:
|
Retina Institute of California, Pasadena, California 91105, USA.tchang@retina2020.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiogenesis Inhibitors / administration & dosage* Antibodies, Monoclonal / administration & dosage* Antibodies, Monoclonal, Humanized Choroidal Neovascularization / drug therapy*, etiology, physiopathology Female Fluorescein Angiography Humans Injections Macular Degeneration / complications, drug therapy*, physiopathology Male Retina / pathology Retrospective Studies Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A / antagonists & inhibitors Visual Acuity / physiology Vitreous Body |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovasculariza...
Next Document: FUNCTIONAL OUTCOME OF INDOCYANINE GREEN-ASSISTED MACULAR SURGERY: 7-Year Follow-Up.